Trial intelligence / Profile preview

Tocilizumab versus adalimumab plus methotrexate in rheumatoid arthritis after inadequate response to one TNF inhibitor

2010-023587-40Phase 4Completed

Sponsor: Roche
Start: Feb 2011
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 4, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Tocilizumab + methotrexate with Adalimumab + methotrexate (2 arms). Primary endpoint: Clinical remission at Week 24. Started Feb 2011; status: completed.

Drugs

tocilizumabadalimumabmethotrexate

Conditions

rheumatoid arthritis (RA)

Beyond the preview

Go deeper on 2010-023587-40.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2010-023587-40.